Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2011

View Archived Issues

New cannabinoid CB2 receptor agonists discovered

AstraZeneca patents new diacylglycerol O-acyltransferase 1 inhibitors

New melanin-concentrating hormone MCH1 receptor antagonists disclosed

Merck & Co. claims novel gamma-secretase modulators

Chimerix begins enrollment in open-label study of CMX-001

Antimalarial artesunate has anticancer properties that can be enhanced by combination therapy

PC-1005 gel protects monkeys from infection with simian HIV

Studies examine pharmacodynamics and antidepressant efficacy of LY-2216684

Zydus-Cadila discloses new GPR119 receptor agonists

Immutep and GSK enter into agreement for ImmuTune IMP-731

Cylene Pharmaceuticals identifies novel protein kinase inhibitors

Isis expands pipeline with ISIS-STAT3Rx and ISIS-FGFR4Rx

NPS Pharma concludes treatment in phase III STEPS trial of Gattex

CeNeRx BioPharma begins phase II trial of modified-release CX-157

Daiichi Sankyo launches Cravit intravenous injections in Japan

MacroGenics begins phase I study of MGAH-22 in HER2-positive tumors

Bristol-Myers Squibb and Pharmasset to evaluate combination treatment for chronic hepatitis C

Phase III trial begins for lubiprostone in opioid-induced bowel dysfunction

Seattle Genetics and Pfizer join to develop anticancer antibody-drug conjugates

New unbiased approach described for discovery of IgG biomarkers with diagnostic potential

Esperion begins phase II trial of ETC-1002 in lipid regulation

Phase II data reported on LCP-Tacro in de novo liver transplant recipients

Dara BioSciences presents additional data from phase I DB-959 trial

EffRx Pharma submits NDA to FDA for EX-101

FDA grants marketing approval for diaDexus' automated PLAC test

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...